Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Oct;61(10):903-8.
doi: 10.1136/thx.2005.056887. Epub 2006 Jun 29.

Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas

J-Y Wang  1 , P-R Hsueh, I-S Jan, L-N Lee, Y-S Liaw, P-C Yang, K-T Luh
Affiliations

Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas

J-Y Wang et al. Thorax. 2006 Oct.

Abstract

Background: A study was conducted to evaluate the effect of the empirical use of fluoroquinolones on the timing of antituberculous treatment and the outcome of patients with tuberculosis in an endemic area.

Methods: All patients with culture confirmed tuberculosis aged > or =14 years diagnosed between July 2002 and December 2003 were included and their medical records were reviewed.

Results: Seventy nine (14.4%) of the 548 tuberculosis patients identified received a fluoroquinolone (FQ group), 218 received a non-fluoroquinolone antibiotic (AB group), and 251 received no antibiotics before antituberculous treatment. Fifty two (65.8%) experienced clinical improvement after fluoroquinolone use. In the FQ group the median interval from the initial visit to starting antituberculous treatment was longer than in the AB group and in those who received no antibiotics (41 v 16 v 7 days), and the prognosis was worse (hazard ratio 6.88 (95% CI 1.84 to 25.72)). More patients in the FQ and AB groups were aged >65 years (53.2% and 61.0% v 31.5%), had underlying disease (53.2% and 46.8% v 34.3%), and were hypoalbuminaemic (67.2% and 64.9% v 35.1%). Of the nine mycobacterial isolates obtained after fluoroquinolone use from nine patients whose initial isolates were susceptible to ofloxacin, one (11.1%) was resistant to ofloxacin (after fluoroquinolone use for 7 days). Independent factors for a poor prognosis included empirical fluoroquinolone use, age >65, underlying disease, hypoalbuminaemia, and lack of early antituberculous treatment.

Conclusions: 14.4% of our patients with tuberculosis received a fluoroquinolone before the diagnosis. With a 34 day delay in antituberculous treatment and more frequent coexistence of underlying disease and hypoalbuminaemia, empirical fluoroquinolone treatment was associated with a poor outcome. Mycobacterium tuberculosis isolates could obtain ofloxacin resistance within 1 week.

PubMed Disclaimer

Conflict of interest statement

Competing interests: none declared.

References

    1. Bartlett J G, Dowell S F, Mandell L A.et al Practice guidelines for the management of community‐acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 200031347–382. - PMC - PubMed
    1. Neu H C. Clinical use of the quinolones. Lancet 198721319–1322. - PubMed
    1. Van Landuyt H W, Magerman K, Gordts B. The importance of the quinolones in antibacterial therapy. J Antimicrob Chemother 199026(Suppl D)1–6. - PubMed
    1. Huang E S, Stafford R S. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 200216241–47. - PubMed
    1. Yew W W, Piddock L J, Li M S.et al In‐vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 199434343–351. - PubMed